Upcoming Virtual Conferences
Pri-Med has more virtual education planned, view our upcoming virtual conference schedule.
Agenda
CME/CE Accredited Session
Non-CME/CE Session
Sponsored by Industry
Click For Session Details
Session Times Listed in ET
8–9am ET CME/CE Accredited Session
Update on Inflammation in Cardiovascular Disease: No Longer a Theory
Peter Libby, MD
After implementing current guideline-directed medical management, there is still urgency to address residual cardiovascular risk. Among the drivers of residual cardiovascular risk, inflammation has generated considerable interest, first based on preclinical and biomarker studies in humans. More recently, translation has inspired clinical trials in this domain. This presentation will consider inflammation as a process that links traditional and nontraditional risk factors to atherothrombotic events.
Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 12/02/2020, and they are subject to change as new information is published.
Peter Libby, MD
Cardiovascular Medicine Specialist, Brigham and Women's Hospital, Mallinckrodt Professor of Medicine, Harvard Medical School, Boston, MA
9:10–10:10am ET CME/CE Accredited Session
Cardiovascular Involvement in COVID-19: The Good, the Bad, and the Unknown
Ty J. Gluckman, MD, FACC, FAHA
This presentation will review the various effects that COVID-19 may have on the cardiovascular system, with a focus on acute cardiac injury, myocarditis, and arrhythmias.
Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 12/02/2020, and they are subject to change as new information is published.
Ty J. Gluckman, MD, FACC, FAHA
Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, OR
10:20–11:05am ET Non-CME Industry Theater
The Interconnected Cardio-Renal-Metabolic (CRM) Systems
John E. Anderson, MD | Narenda Singh, MD, FRCPC, FCCS, FACC, FAHA
The objectives of the program are to:
- Review the interconnected nature of the CRM systems
- Identify the shared risk factors that contribute to the development and progression of clinically comorbid conditions within these systems
- Discuss the impact of coexisting conditions of the CRM systems and the continuum of risk
- Highlight a collaborative care approach for patients who are at risk for or have established disorders of the CRM systems
John E. Anderson, MD
Internal Medicine and Diabetes, The Frist Clinic, Nashville, TN
Narenda Singh, MD, FRCPC, FCCS, FACC, FAHA
Clinical Assistant Professor, Medical College of Georgia at Augusta University, Director, Clinical Research-NSC Cardiology, Johns Creek, Georgia
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC
10:20–11:05am ET Non-CME Industry Theater
Early Recognition of axSpA in Primary Care Chapter 4: Sex differences in patients with axSpA
Abhijeet S. Danve, MBBS, MD, FACP
View this presentation to learn more about the important role of primary care providers in the early recognition of axSpA. This presentation is the fourth chapter of a series of videos exploring axSpA.
Join us for a live webinar with Dr. Danve on December 2 at 10:20 AM ET.
Abhijeet S. Danve, MBBS, MD, FACP
MD, FACP, Rheumatologist, Assistant Professor of Medicine,, Director, Yale Spondyloarthritis Program, Yale School of Medicine
Sponsored by Novartis Pharmaceuticals Corporation
11:15am–12:30pm ET CME/CE Accredited Session
Advances and Strategies in Lipid Management to Prevent ASCVD Events
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, FACP, FCCP | William E. Boden, MD, FACC, FAHA
This session will review the recent cardiovascular outcomes trials and their clinical implications in reducing ASCVD events. The expert faculty will also discuss the practical usage of therapies targeting ASCVD event reduction as adjuncts to statin therapy to reduce residual ASCVD risk.
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, FACP, FCCP
Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital Heart & Vascular Center, Professor of Medicine, Harvard Medical School, Boston, MA
William E. Boden, MD, FACC, FAHA
Professor of Medicine, Boston University School of Medicine, Lecturer in Medicine, Harvard Medical School, Physician Research Lead & Scientific Director, Clinical Trials Network, VA New England Healthcare System, VA Boston – Jamaica Plain Campus, Boston, MA
Supported by Amarin Pharma Inc.
12:40–1:25pm ET Non-CME Industry Theater
Close to the Heart: The Importance of Recognizing Cardiovascular Risk in Type 2 Diabetes
Javier Morales, MD, FACP, FACE
The objective of this program is to communicate the importance of addressing cardiovascular risk in patients with type 2 diabetes. The program will cover data on prevalence, morbidity, mortality, and intensive versus conventional glucose lowering on macrovascular complications. In addition, the program will review guidance from leading medical associations that is based upon completed cardiovascular outcome trials of antihyperglycemic medications in patients with type 2 diabetes.
Javier Morales, MD, FACP, FACE
FACP, FACE, Vice President, Advanced Internal Medicine Group, East Hills, New York
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC